Correspondence 0000950170-24-110267 from Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: Sept. 30, 2024 · CIK: 0001404281 · Accession: 0000950170-24-110267
AI Filing Summary & Sentiment
File numbers found in text: 333-282260
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christopher Edwards Registration Statement on Form S-3 (File No. 333-282260)
Re: Request for Effectiveness for Eledon Pharmaceuticals, Inc.
Dear Mr. Edwards:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on October 2, 2024, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above.
Very truly yours,
Eledon Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 30, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christopher Edwards Re: Request for Effectiveness for Eledon Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-282260) Dear Mr. Edwards: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on October 2, 2024, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968. If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above. Very truly yours, Eledon Pharmaceuticals, Inc. By: /s/ Paul Little Name: Paul Little Title: Chief Financial Officer cc: Shelly Heyduk, O’Melveny & Myers LLP